{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon-beta+%28IFN-beta%29&page=5", "query": { "intervention": "Interferon-beta (IFN-beta)", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 128, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon-beta+%28IFN-beta%29&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon-beta+%28IFN-beta%29&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T14:06:40.141Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00893217", "title": "BEYOND Pilot Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis", "Relapsing-Remitting" ], "interventions": [ { "name": "Betaseron (Interferon beta-1b, BAY86-5046)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 71, "start_date": "2002-11", "completion_date": "2003-06", "has_results": false, "last_update_posted_date": "2009-11-09", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 14, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00893217" }, { "nct_id": "NCT01067573", "title": "The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 20, "start_date": "2009-12", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2012-06-18", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01067573" }, { "nct_id": "NCT00099502", "title": "BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)", "type": "DRUG" }, { "name": "Copaxone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 2244, "start_date": "2003-11", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2008-12-19", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00099502" }, { "nct_id": "NCT00548405", "title": "Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Alemtuzumab 12 mg", "type": "BIOLOGICAL" }, { "name": "Alemtuzumab 24 mg", "type": "BIOLOGICAL" }, { "name": "Interferon beta-1a", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 840, "start_date": "2007-10", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 85, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00548405" }, { "nct_id": "NCT00436826", "title": "A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Interferon-beta (IFN-beta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 172, "start_date": "2006-11-30", "completion_date": "2012-03-31", "has_results": true, "last_update_posted_date": "2020-10-12", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 21, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436826" }, { "nct_id": "NCT01207648", "title": "Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Rebif®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 307, "start_date": "2010-07", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2015-05-15", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01207648" }, { "nct_id": "NCT00050778", "title": "A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Interferon beta-1a", "type": "BIOLOGICAL" }, { "name": "Alemtuzumab 12 mg", "type": "BIOLOGICAL" }, { "name": "Alemtuzumab 24 mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 334, "start_date": "2002-12", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 31, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00050778" }, { "nct_id": "NCT00599274", "title": "Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Interferon beta-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 136, "start_date": "2002-08", "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2010-01-27", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 8, "location_summary": "Los Angeles, California • Walnut Creek, California • Shreveport, Louisiana + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00599274" }, { "nct_id": "NCT05688436", "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Diroximel Fumarate", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Fingolimod", "type": "DRUG" }, { "name": "Glatiramer acetate", "type": "DRUG" }, { "name": "Interferon beta", "type": "BIOLOGICAL" }, { "name": "Natalizumab", "type": "BIOLOGICAL" }, { "name": "Ocrelizumab", "type": "BIOLOGICAL" }, { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Ozanimod", "type": "DRUG" }, { "name": "Peginterferon beta-1a", "type": "BIOLOGICAL" }, { "name": "Ponesimod", "type": "DRUG" }, { "name": "Siponimod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 1178, "start_date": "2021-09-24", "completion_date": "2031-01-17", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 1, "location_summary": "Eden Prairie, Minnesota", "locations": [ { "city": "Eden Prairie", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05688436" }, { "nct_id": "NCT02269930", "title": "Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "peginterferon beta-1a", "type": "DRUG" }, { "name": "Rebif", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 30, "start_date": "2014-10", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-02-02", "last_synced_at": "2026-11-15T14:06:40.141Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269930" } ] }